Cancer
2 Results were found on Technologies
Sub Category Name
OGP: A CB2 Agonist Enhancing CAR-T Therapy
CAR-T therapies show promising clinical responses, yet many patients relapse due to the immunosuppressive tumor microenvironment (TME). Multiple Myeloma remains largely incurable. OUR SOLUTION Osteogenic growth peptide (OGP), a selective CB2 agonist, enhances anti-tumor immunity by reducing immunosuppressive myeloid cells and boosting cytotoxic T-cell activity. In preclinical studies, OGP demonstrated synergistic activity with CAR-T therapy, […] Read More >
OGP: Immune-Modulating Cancer Therapy
Osteogenic growth peptide (OGP), a selective CB2 agonist, reduces cancer progression in two models of colon cancer and one model of breast cancer in mice by modulating immune responses. Human genetic data supports the role of CB2 in tumor immunology. UNMET NEED Colon carcinoma and breast cancer are prevalent solid tumors with limited therapies and […] Read More >
